ABT-510 and Bevacizumab in Treating Patients With Advanced Solid Tumors

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed advanced solid tumor
• Refractory to standard therapy or for which there is no standard therapy

• No known brain metastases

  • Patients with primary malignancies known to metastasize to the brain (such as lung cancer, breast cancer, renal cell cancer, sarcoma, carcinoma of unknown primary, melanoma, or head and neck cancers) or patients with symptoms of brain metastases should have a brain MRI within 28 days of enrollment to confirm the absence of CNS metastases

    • Contrast CT scan is acceptable for patients who are unable to undergo a brain MRI
• No squamous cell carcinoma of the lung

PATIENT CHARACTERISTICS:

• ECOG performance status 0-1
• Hemoglobin ≥ 9.0 g/dL
• Absolute neutrophil count ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• Bilirubin ≤ 1.5 times upper limit of normal (ULN)
• PT/INR/PTT ≤ 1.2 times ULN
• AST/ALT ≤ 2.5 times ULN (5 times ULN if known hepatic metastases)
• Urine protein:creatinine ≤ 1.0 (spot urine sample)
• Creatinine clearance ≥ 50 mL/min
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during the study and for up to 4 months after study completion
• No New York Heart Association class III or IV heart disease
• No angina requiring nitrates
• No myocardial infarction in the past 6 months
• No cerebrovascular accident or transient ischemic attack in the past 6 months
• No thrombosis within 3 months
• No poorly controlled hypertension (i.e., blood pressure > 160/100 mm Hg)
• No ventricular arrhythmia requiring medication
• No poorly controlled or clinically significant atherosclerotic vascular disease
• No coagulopathy
• No presence of bleeding diathesis
• No non-healing wounds
• No gastrointestinal (GI) perforation within past 6 months
• No acute GI bleed requiring transfusion or invasive intervention within the past 6 months
• No hemoptysis greater than 1 tablespoon within 6 months
• No other major bleeding event
• No history of intra-abdominal fistula or abscess within the past 6 months
• No uncontrolled intercurrent illness
• No history of intolerance to bevacizumab or ABT-510
• No ongoing or active infection
• No psychiatric illness or social situations that would limit safety or compliance with study requirements
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for at least 3 months after study participation

PRIOR CONCURRENT THERAPY:

• No angioplasty in the past 6 months
• No cardiac or vascular stenting in the past 6 months
• Patients with prostate cancer who are already receiving androgen deprivation therapy (i.e., leuprolide or goserelin) for longer than 3 months may continue on this therapy during the study
• No major surgery within past 28 days
• No other investigational agents within the past 28 days
• No chemotherapy for cancer within past 21 days
• No biologic therapy for cancer within past 21 days
• No radiation therapy within past 21 days
• No hormonal therapy within past 21 days
• No minor surgical procedures within past 14 days

• Initiation or adjustment of blood pressure (BP) medication is permitted prior to study entry

  • Must have 3 consecutive BP readings less than 150/90 mm Hg

    • Each reading must be separated by a minimum of 24 hours

• No concurrent use of therapeutic anticoagulation

  • Prophylactic low-dose anticoagulation for indwelling catheter is permitted provided PT/PTT is within normal limits
• No use of antiplatelet agents other than aspirin (< 325 mg/day) or standard dose nonsteroidal anti-inflammatory drugs